novo nordisk news - Search News

Novo Nordisk raises expectations for Eli Lilly

Will Novo Nordisk (NVO) Stock Recover To $145 Levels?

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over this period.

Hosted on MSN · 1d

Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.

The Motley Fool · 4d

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Christmas, Novo Nordisk and European markets

MarketWatch on MSN · 2d

Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said

CNBC on MSN · 1d

European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recovery

European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 was up by around 0.3% during morning deals, with all sectors in positive territory.

Seeking Alpha on MSN · 1d

European markets turn green ahead of Christmas break

London (UKX) +0.33% will close early for Christmas. Germany (DAX:IND) closed for Chritsmas France (CAC:IND) +0.38% set to close early. Prime Minister François Bayrou pledged to cut the country's budget deficit to near 5%.

21h

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

4don MSN

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

4d

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

4don MSN

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

4don MSN

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

4d

Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

1d

FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza

Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...

Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results